Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00237978 |
Recruitment Status : Unknown
Verified May 2008 by Technische Universität Dresden.
Recruitment status was: Recruiting
First Posted : October 13, 2005
Last Update Posted : May 14, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acne Papulopustulosa | Drug: Adapalen Radiation: VIS and wIRA | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel) |
Study Start Date : | September 2006 |
Estimated Primary Completion Date : | June 2009 |
Estimated Study Completion Date : | September 2009 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
VIS and wIRA
|
Radiation: VIS and wIRA |
Active Comparator: 2
VIS, wIRA and Adapalen
|
Drug: Adapalen Radiation: VIS and wIRA |
Active Comparator: 3
Adapalen
|
Drug: Adapalen |
- reduction of inflammatory and non-inflammatory lesions within 8 weeks after start of therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 14 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mild to moderate acne papulopustulosa according to Burton Scale Stage 3 to 4
- At least 5 inflammatory and 5 non-inflammatory lesions in the face
- Age >= 14 years
Exclusion Criteria:
- pregnant and nursing women
- Antiandrogen therapy
- therapy with antibiotics within the last 4 weeks
- therapy with retinoids within the last 6 months
- natural or artificial UV-therapy within the last 4 weeks
- severe acne papulopustulosa according to Burton Scale 5 or 6
- Severe systemic condition
- Secondary acne

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00237978
Contact: Roland Aschoff, MD | 0049-351-458 ext 2007 | Roland.Aschoff@mailbox.tu-dresden.de |
Germany | |
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden | Recruiting |
Dresden, Sachsen, Germany, 01307 | |
Contact: Roland Aschoff, MD 0049-351-458 ext 2007 Roland.Aschoff@mailbox.tu-dresden.de |
Principal Investigator: | Roland Aschoff, MD | Technische Universität Dresden, Fetscher Str. 74, 01307 Dresden, Germany |
Responsible Party: | Roland Aschoff, MD, Technical University Dresden |
ClinicalTrials.gov Identifier: | NCT00237978 |
Other Study ID Numbers: |
TUD-Akne02-003 |
First Posted: | October 13, 2005 Key Record Dates |
Last Update Posted: | May 14, 2009 |
Last Verified: | May 2008 |
Acne Vulgaris Acneiform Eruptions Skin Diseases Sebaceous Gland Diseases |